ArticlePituitary2026
Gender differences in surgical outcomes and predictors of long term endocrine and metabolic morbidity in adults with craniopharyngioma.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze surgical outcomes in adults with craniopharyngioma (CP) and to identify predictors of long-term endocrine-metabolic morbidity.
methodsRetrospective, bi-institutional cohort study of adults (≥ 18 y) treated at Ramón y Cajal University Hospital (Spain) or the University of South Florida Endocrinology & Diabetes Center (USA). Uniform endocrine protocols and ≥ 1 year of postoperative follow-up were required. Paired axis-by-axis hormonal assessment, body mass index (BMI) tracking, and registry-matched standardized prevalence ratios (SPR) for diabetes, hypertension and dyslipidemia were estimated.
resultsFifty-one histologically confirmed CP patients (19 women and 32 males) were included. The median follow-up was 6 years (range 3–21). At diagnosis, men had larger tumors (3.0 ± 0.9 vs. 2.4 ± 0.7 cm; p = 0.038), more mixed solid–cystic morphology (72% vs. 46%; p = 0.030) and a higher prevalence of LH/FSH deficiency (41% vs. 7%, p = 0.043). Transsphenoidal surgery predominated (71%) and gross total resection was achieved in 63% of the patients. Radiotherapy was the only independent predictor of persistent visual loss (odds ratio [OR] = 1.62; p = 0.002). At last follow-up, 44% of the patients acquired ≥ 1 new pituitary deficit, most frequently of TSH (24%) and ACTH (30%); craniotomy independently increased the number of altered axes (p = 0.001) and being male independently predicted new-onset TSH deficiency (OR = 1.3 [1.1–2.1], p = 0.003). Obesity prevalence remained high after surgery (71%) and suprasellar location predicted higher final BMI (OR = 5.3; p = 0.014). Diabetes was markedly over-represented (SPR 3.64 for Spain; 2.53 for USA), whereas hypertension SPRs were neutral and dyslipidemia was 70% higher in Spain. Radiotherapy, residual tumor and BMI independently predicted metabolic outcomes.
conclusionsDespite curative-intended surgery adult survivors with CP experience substantial endocrine and metabolic morbidity, driven by tumor topography, surgical route and adjuvant radiotherapy. Lifelong, multidisciplinary surveillance—coupling endocrine replacement with aggressive cardiometabolic management—is essential to mitigate this burden.
Indexed as
Identifiers
41721132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.